StreetInsider.com News Articles

Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Mon, 27 Jul 2026 09:50:00 -0400

TOKYO, Jul 27, 2026 - (JCN Newswire) - - Pfizer Japan Inc. (Headquarters: Tokyo, President and Representative Director: Hiroo Igarashi, "Pfizer") and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the companies will commence the co-promotion of the oral calcitonin gene-related peptide (CGRP) receptor antagonist Nurtec(R) OD Tablet 75mg (generic name: rimegepant sulfate hydrate, hereinafter "Nurtec") in Japan from September 1, 2026.

Nurtec is an oral CGRP receptor antagonist, indicated for both acute treatment and prophylaxis of migraine.

This co-promotion aims to facilitate the timely and broad dissemination of information on the appropriate use of Nurtec in

Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Mon, 27 Jul 2026 09:50:00 -0400

Nurtec is an oral CGRP receptor antagonist, indicated for both acute treatment and prophylaxis of migraine.

This co-promotion aims to facilitate the timely and broad dissemination of information on the appropriate use of Nurtec in

Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Mon, 27 Jul 2026 09:50:00 -0400

Nurtec is an oral CGRP receptor antagonist, indicated for both acute treatment and prophylaxis of migraine.

This co-promotion aims to facilitate the timely and broad dissemination of information on the appropriate use of Nurtec in

Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Mon, 27 Jul 2026 09:50:00 -0400

Nurtec is an oral CGRP receptor antagonist, indicated for both acute treatment and prophylaxis of migraine.

This co-promotion aims to facilitate the timely and broad dissemination of information on the appropriate use of Nurtec in

Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Mon, 27 Jul 2026 09:50:00 -0400

Nurtec is an oral CGRP receptor antagonist, indicated for both acute treatment and prophylaxis of migraine.

This co-promotion aims to facilitate the timely and broad dissemination of information on the appropriate use of Nurtec in

Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Mon, 27 Jul 2026 09:50:00 -0400

Nurtec is an oral CGRP receptor antagonist, indicated for both acute treatment and prophylaxis of migraine.

This co-promotion aims to facilitate the timely and broad dissemination of information on the appropriate use of Nurtec in

Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Mon, 27 Jul 2026 09:50:00 -0400

Nurtec is an oral CGRP receptor antagonist, indicated for both acute treatment and prophylaxis of migraine.

This co-promotion aims to facilitate the timely and broad dissemination of information on the appropriate use of Nurtec in

Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine

Mon, 27 Jul 2026 09:50:00 -0400

Nurtec is an oral CGRP receptor antagonist, indicated for both acute treatment and prophylaxis of migraine.

This co-promotion aims to facilitate the timely and broad dissemination of information on the appropriate use of Nurtec in

EMA accepts Eisai's lemborexant application for insomnia treatment

Fri, 17 Jul 2026 19:21:25 -0400

Eisai Co., Ltd. announced that the European Medicines Agency (EMA) has accepted for evaluation a marketing authorization application (MAA) for lemborexant, an orexin receptor antagonist developed in-house by the Tokyo-based pharmaceutical company, for the treatment of adult patients with chronic insomnia.

Lemborexant is a dual orexin receptor antagonist that works by binding competitively to two subtypes of orexin receptors (OX1R and OX2R), inhibiting orexin neurotransmission that regulates sleep and wake states.

Chronic insomnia is characterized by difficulty falling or staying asleep for at least three months. In Europe, the condition is reported to affect approximately 4.7% to 22.1% of adults.

Lemborexant has already

EMA accepts Eisai's lemborexant application for insomnia treatment

Fri, 17 Jul 2026 19:21:25 -0400

Chronic insomnia is characterized by difficulty falling or staying asleep for at least three months. In Europe, the condition is reported to affect approximately 4.7% to 22.1% of adults.

Lemborexant has already

EMA accepts Eisai's lemborexant application for insomnia treatment

Fri, 17 Jul 2026 19:21:25 -0400

Chronic insomnia is characterized by difficulty falling or staying asleep for at least three months. In Europe, the condition is reported to affect approximately 4.7% to 22.1% of adults.

Lemborexant has already

EMA accepts Eisai's lemborexant application for insomnia treatment

Fri, 17 Jul 2026 19:21:25 -0400

Chronic insomnia is characterized by difficulty falling or staying asleep for at least three months. In Europe, the condition is reported to affect approximately 4.7% to 22.1% of adults.

Lemborexant has already

EMA accepts Eisai's lemborexant application for insomnia treatment

Fri, 17 Jul 2026 19:21:25 -0400

Chronic insomnia is characterized by difficulty falling or staying asleep for at least three months. In Europe, the condition is reported to affect approximately 4.7% to 22.1% of adults.

Lemborexant has already

EMA accepts Eisai's lemborexant application for insomnia treatment

Fri, 17 Jul 2026 19:21:25 -0400

Chronic insomnia is characterized by difficulty falling or staying asleep for at least three months. In Europe, the condition is reported to affect approximately 4.7% to 22.1% of adults.

Lemborexant has already

Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)

Fri, 17 Jul 2026 10:24:00 -0400

TOKYO, Jul 17, 2026 - (JCN Newswire) - - Eisai Co., Ltd. announced today that the European Medicines Agency (EMA) has accepted for evaluation a marketing authorization application (MAA) for its in-house-discovered and developed orexin receptor antagonist lemborexant (generic name) for the treatment of adult patients with chronic insomnia.

Lemborexant is a dual orexin receptor antagonist (DORA) that inhibits orexin neurotransmission regulating sleep and wake states by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R).1 Lemborexant acts on the orexin neurotransmitter system, which regulates wakefulness. Lemborexant is believed to facilitate sleep onset and decrease wakefulness during

Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)

Fri, 17 Jul 2026 10:24:00 -0400

Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)

Fri, 17 Jul 2026 10:24:00 -0400

Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)

Fri, 17 Jul 2026 10:24:00 -0400

Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)

Fri, 17 Jul 2026 10:24:00 -0400

Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)

Fri, 17 Jul 2026 10:24:00 -0400

FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's

Wed, 15 Jul 2026 13:29:13 -0400

Eisai Co. and Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration has approved a supplemental Biologics License Application for a once-weekly subcutaneous injection of lecanemab-irmb, marketed as Leqembi Iqlik, as an initiation dose for the treatment of early Alzheimer's disease.

Leqembi Iqlik is administered via an autoinjector at 500 mg once weekly, delivered as two 250 mg injections, each taking approximately 15 seconds. The approval introduces an at-home administration option as an alternative to intravenous infusion from the start of treatment. After 18 months of either intravenous or subcutaneous treatment, patients may transition to a maintenance dose

FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's

Wed, 15 Jul 2026 13:29:13 -0400

FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's

Wed, 15 Jul 2026 13:29:13 -0400

FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's

Wed, 15 Jul 2026 13:29:13 -0400

FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's

Wed, 15 Jul 2026 13:29:13 -0400